The American Journal of Medicine
Volume 121, Issue 4 , Pages 253-255 , April 2008

Doctors and the Drug Industry: Further Thoughts for Dealing with Potential Conflicts of Interest?

References 

  1. Alpert JS. Doctors and the drug industry: How can we handle potential conflicts of interest?. Am J Med. 2005;118:99–100
  2. Morin K, Rakatansky H, Riddick FA, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002;287:78–84
  3. Korn D. Conflicts of interest in biomedical research. JAMA. 2000;284:2234–2238
  4. Cech TR, Leonard JS. Conflicts of interest—moving beyond disclosure. Science. 2001;291:989
  5. Lo B, Wolf LE, Berkeley A. Conflict of interest policies for investigators in clinical trials. N Eng J Med. 2000;343:1616–1620
  6. La Puma J. Physicians’ conflict of interest in post-marketing research: What the public should know, and why industry should tell them. Research Ethics and Human Subjects: Facing the 21st Century. Frederick, MD: University Publishing Group; 1995;
  7. Federman DD, Hanna KE, Rodriguez LL, et al. Responsible Research—A Systems Approach to Protecting Research Participants. Washington, DC: The National Academies Press; 2003;
  8. Levinsky NG. Non financial conflicts of interest in research. N Engl J Med. 2002;347:759–761
  9. Committee on Assessing the System for Protecting Human Research Subjects. Preserving Public Trust: Accreditation and Human Research Participant Protection Programs. Washington, DC: National Academy Press; 2001;
  10. Alpert JS, Furman S, Smaha L. Conflicts of interest. Arch Intern Med. 2002;162:635–637
  11. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–1890
  12. Mitka M. Researchers critical of TV drug ads. JAMA. 2007;297:939–940
  13. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians’ relationship with the pharmaceutical industry—Self regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891–1900
  14. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. JAMA. 2000;283:373–380
  15. Keim SM, Mays MZ, Grant D. Interactions between emergency medicine programs and the pharmaceutical industry. Acad Emerg Med. 2004;11:19–26
  16. Komesaroff PA, Kerridge IH. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Med J Aust. 2002;176:118–121
  17. Chren M. Interactions between physicians and drug company representatives. Am J Med. 1999;107:182–183
  18. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? (A survey of physicians). Arch Intern Med. 2003;163:2213–2218
  19. Mizik N, Jacobson R. Are physicians “easy marks”? (Quantifying the effects of detailing and sampling on new prescriptions). Management Science. 2004;December
  20. Relman AS, Angell M. America’s other drug problem. The New Republic. 2002;27–41December 16
  21. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff (Millwood). 2004;23(1):107–112

PII: S0002-9343(08)00053-3

doi: 10.1016/j.amjmed.2008.01.010

The American Journal of Medicine
Volume 121, Issue 4 , Pages 253-255 , April 2008

Article Tools